

Curriculum Vitae

Martin Wetzke Professor Dr. med.

Current Position

Attending physician at Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School (MHH); Head Non-CF Bronchiectasis Program

Principal Investigator, German Center for Lung Research (DZL), BREATH Consortium, Hannover Disease Area: Pneumonia and Acute Lung Injury (ALI), Cystic Fibrosis & Bronchiectasis (CFBE)

University Education

2026 Adjunct Professorship Paediatrics, Hannover Medical School
2021 Habilitation/Venia legendi Pediatrics, Hannover Medical School
2011 Doctorate Medicine (Dr. med.), LMU, summa cum laude
2000–2007 Studies of Medicine, Ludwig-Maximilians-University Munich/Technical University of Munich/Columbia University, New York (USA)

Scientific Career

2025 Board Member, Kinderlungenregister KLR e.V. (International Registry and Biobank for Rare Lung Diseases / child.eu)
2025 Speaker, Working Group Bronchoscopy, German Society for Pediatric Pneumology
2024 Call to W2 University Professorship in Pediatric Pneumology, University Medicine Rostock (declined)
2023 Call to W2 University Professorship in Pediatric Pneumology, University Medicine Bochum (declined)
2021 Habilitation (Venia Legendi), Hannover Medical School; "Respiratory Infections in Pediatrics – New Aspects of Susceptibility, Management and Therapy"
2019 Qualification Medical Education, Center for Higher Education Didactics, TU Braunschweig
2015-2019 Clinician Scientist, Institute for Experimental Virology (TWINCORE, Hannover)
2012-2015 Fellowship Pediatric Pneumology, Pediatric Allergology, Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School (MHH)
2017–2012 Residency, Pediatric & Adolescent Medicine, Hannover Medical School

Academic activities, awards

2025 Board Member, Kinderlungenregister KLR e.V. (International Registry and Biobank for Rare Lung Diseases / child.eu)
2025 Speaker, Working Group Bronchoscopy, German Society for Pediatric Pneumology
2023 Principal Investigator, German Center for Lung Research (DZL), BREATH
2023 Member, AWMF Guideline Commission (RSV prophylaxis in high-risk children; Atemwegsendsoskopie im Kindesalter)
2020 Coordinator, AWMF S2k Guideline: "Management of virus-induced obstructive respiratory illness in infancy"
2017-2022 Member, Sino-German RSV Research Initiative "Qilu-Helmholtz International Collaboration RSV"
2009–2019 Poster Awards: German Society for Pediatric Pneumology (GPP), DGAKI, DGKJ

Citation Record

Total citations: 4659; h-index:35; h-index since 2021: 21 (Google Scholar April, 2026)

Top-10 selected Publications

Kiefer A, Twardella D, Bähre J, Behrens C, Buck T, Eberhardt F, Bangert M, Kramer R, Gerber A, Rosewich M, Schaaff F, Höpner JH, Panning M, Kabesch M, Happle C, **Wetzke M**. Primary care RSV disease characteristics in infants and young children in Germany, data from the prospective PAPI surveillance network, 2021-2023. *Int J Infect Dis*. 2026 Mar 1:108509. doi:10.1016/j.ijid.2026.108509.

Wetzke M, Lange M, Koerner-Rettberg C, Kiefer A, Kabesch M, Armbrust S, Abdelkhalek K, Lex C, Hufnagel M, Bode S, Dördelmann M, Lorenz M, Arens S, Panning M, Köster H, Kramer R, Bangert M, Eberhardt F, Barten-Neiner G, Happle C. RSV is the main cause of severe respiratory infections in infants and young children in Germany - data from the prospective, multicenter PAPI study 2021-2023. *Infection*. 2025 Oct;53(5):1715-1723. doi: 10.1007/s15010-025-02484-1. Epub 2025 Feb 19. PMID: 39971837;

Wetzke M, Le DB, Tometten I, Ritter S, Lübke N, Timm J, Dilthey A, Panning M, Walker A, Happle C. Prevalence of Resistance-Associated Mutations in RSV F Protein Against Monoclonal Antibodies Prior to Widespread Implementation: Findings From a Prospective German Pediatric Cohort. *Influenza Other Respir Viruses*. 2025 Sep;19(9):e70164. doi: 10.1111/irv.70164. PMID: 40967634;

Wetzke M, Schütz K, Kopp M, Seidenberg J, Vogelberg C, Ankermann T, Happle C, Voigt G, Köster H, Illig T, Lex C, Schuster A, Maier R, Panning M, Barten G, Rohde G, Welte T, Hansen G. Pathogen spectra in hospitalised and non-hospitalised children with community acquired pneumonia. *ERJ Open Res*. 2022. *ERJ Open Res*. 2023 Mar 13;9(2):00286-2022. doi: 10.1183/23120541.00286-2022. eCollection 2023 Mar. PMID: 36923566.

Windrich J, Braubach P, Länger F, Dingemann J, Schwerk N, **Wetzke M**, Renz DM, Zenker M, Schanze D, Kratz CP. RAS-MAPK Pathway Mutations in Congenital Pulmonary Airway Malformations. *Am J Respir Crit Care Med*. 2024 May 15;209(10):1266-1268. doi: 10.1164/rccm.202311-2163LE. PMID: 38377348; PMCID: PMC11146530.

Sake SM, Zhang X, Rajak MK, Urbanek-Quaing M, Carpentier A, Gunesch AP, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee AK, Johnson K, Morwood K, Rox K, Elgaher WAM, Huang J, **Wetzke M**, Hansen G, Fischer N, Eléouët JF, Rameix-Welti MA, Hirsch AKH, Herold E, Empting M, Lauber C, Schulz TF, Krey T, Haid S, Pietschmann T. Drug repurposing screen identifies Ionafarnib as respiratory syncytial virus fusion protein inhibitor. *Nat Commun*. 2024 Feb 8;15(1):1173. doi: 10.1038/s41467-024-45241-y. PMID: 38332002; PMCID: PMC10853176. (IF 15,7)

Li Y, Seidl E, Knoflach K, Gothe F, Forstner ME, Michel K, Pawlita I, Gesenhues F, Sattler F, Yang X, Kroener C, Reu-Hofer S, Ley-Zaporozhan J, Kammer B, Krüger-Stollfuß I, Dinkel J, Carlens J, **Wetzke M**, Moreno-Galdó A, Torrent-Vernetta A, Lange J, Krenke K, Rumman N, Mayell S, Sismanlar T, Aslan A, Regamey N, Proesmans M, Stehling F, Naehrlich L, Ayse K, Becker S, Koerner-Rettberg C, Plattner E, Manali ED, Papiris SA, Campo I, Kappler M, Schwerk N, Griese M. ABCA3-related interstitial lung disease beyond infancy. *Thorax*. 2023 Jun;78(6):587-595. doi: 10.1136/thorax-2022-219434. Epub 2023 Feb 20. PMID: 36808083. (IF 9,2)

Griese M, Seidl E, Hengst M, Reu S, Rock H, Anthony G, Kiper N, Emiralioğlu N, Snijders D, Goldbeck L, Leidl R, Ley-Zaporozhan J, Krüger-Stollfuß I, Kammer B, Wesselak T, Eismann C, Schams A, Neuner D, MacLean M, Nicholson AG, Lauren M, Clement A, Epaud R, de Blic J, Ashworth M, Aurora P, Calder A, **Wetzke M**, Kappler M, Cunningham S, Schwerk N, Bush A; the other chILD-EU collaborators. International management platform for children's interstitial lung disease (chILD-EU). *Thorax*. 2018

Mar;73(3):231-239. doi: 10.1136/thoraxjnl-2017-210519. Epub 2017 Oct 22. PMID: 29056600. (IF 9,139)

Rauch D, **Wetzke M**, Reu S, Wesselak W, Schams A, Hengst M, Kammer B, Ley-Zaporozhan J, Kappler M, Proesmans M, Lange J, Escribano A, Kerem E, Ahrens F, Brasch F, Schwerk N, Griesse M; PTI (Persistent Tachypnea of Infancy) Study Group of the Kids Lung Register. Persistent Tachypnea of Infancy. Usual and Aberrant. *Am J Respir Crit Care Med*. 2016 Feb 15;193(4):438-47. doi: 10.1164/rccm.201508-1655OC. PMID: 26474448. (IF 21,4)

Lachmann N, Happle C, Ackermann M, Lüttge D, **Wetzke M**, Merkert S, Hetzel M, Kensah G, Jara-Avaca M, Mucci A, Skuljec J, Dittrich AM, Pfaff N, Brenning S, Schambach A, Steinemann D, Göhring G, Cantz T, Martin U, Schwerk N, Hansen G, Moritz T. Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. *Am J Respir Crit Care Med*. 2014 Jan 15;189(2):167-82. doi: 10.1164/rccm.201306-1012OC. PMID: 24279725. (IF 21,4)